Immunostimulatory DNA-based vaccines reduce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

Nature Biotechnology

Volumn 18, Issue 5, 2000, Pages 509-514

  Cho, Hearn Jay ^a   Takabayashi, Kenji ^a   Cheng, Pei Ming ^a   Nguyen, Minh Duc ^a   Corr, Maripat ^a   Tuck, Stephen ^b   Raz, Eyal ^a  

^a University of California San Diego School of Medicine   (United States)

^b Dynavax Technologies Corporation   (United States)

Author keywords

AIDS; CpG motif; CTL activation; Immunostimulatory DNA sequences

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OLIGODEOXYNUCLEOTIDE; OVALBUMIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; HELPER CELL; HOST RESISTANCE; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DINUCLEOSIDE PHOSPHATES; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, MUTANT STRAINS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

ANIMALIA;

EID: 0034073872     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/75365     Document Type: Article

References (37)

1. Carson, D. & Raz, E. Oligonucleotide adjuvants for T helper 1 Th1 -specific vaccination. J. Exp. Med. 186, 1621-1622. (1997).
2. Krieg, A.M., Yi, A.K., Schorr, J. & Davis, H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6, 23-27 (1998).
3. Shimada, S. et al. Antitumor activity of the deoxyribonucleic acid fraction of Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J. Natl. Cancer Inst. 74, 681-688 (1985).
4. Tokunaga, T. et al. Antitumor activity of the deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72, 955-962 (1984).
5. Yamamoto, S. et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J. Immunol. 148, 4072-4076 (1992).
6. Martin-Orozco, E. et al. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 11, 1111-1118 (1999).
7. Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995).
8. Lipford, G.B. et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340-2344 (1997).
9. Sato, Y. et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273, 352-354 (1996).
10. Corr, M., Lee, D.J., Carson, D.A. & Tighe, H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184, 1555-1560. (1996).
11. Roman, M. et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3, 849-854 (1997).
12. Horner, A.A. et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190, 77-82 (1998).
13. Chu, R.S., Targoni, O.S., Krieg, A.M., Lehmann, P.V. & Harding, C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 Th1 immunity. J. Exp. Med. 186, 1623-1631 (1997).
14. Davis, H.L. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876 (1998).
15. Keene, J.-A. & Foreman, J. Helper activity is required for the in vivo generation of cytotoxic lymphocytes. J. Exp. Med. 155, 768-782 (1982).
16. Mitchison, N.A. & O'Malley, C. Three-cell-type cluster of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur. J. Immunol. 17, 1579-1583 (1987).
17. Bennett, S.R.M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393, 476-480 (1998).
18. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
19. Schoenberger, S.P., Toes, R.E.M., van der Voort, E.I.H., Offringa, R. & Melief, C.J.M. T-cell help for cytotoxic lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
20. Lin, M.S. & Chen, Y.W. B cell differentiation. II. Isotype potential of a single B cell. Cell. Immunol. 150, 343-352 (1993).
21. Porgador, A., Snyder, D. & Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918-2926 (1996).
22. Lanzavecchia, A. License to kill. Nature 393, 413-414 (1998).
23. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp, Med. 177, 1791-1796 (1993).
24. Grewal, I.S. & Flavell, R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153, 85-106 (1996).
25. Sigal, L.J., Reiser, H. & Rock, K.L. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol. 181, 2740-2745 (1998).
26. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol. 13, 251-276 (1995).
27. Jakob, T, Walker, P.S., Krieg, A.M., Udey, M.C. & Vogel, J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161, 3042-3046 (1998).
28. Kovacsovics-Bankowski, M. & Rock, K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243-246 (1995).
29. Shen, Z., Reznikofl, G., Dranoff, G. & Rock, K. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723-2730 (1997).
30. Reis e Souza, C. & Germain, R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182, 841-851 (1995).
31. Pfeifer, J.D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 359-362 (1993).
32. Gromme, M. et al. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl. Acad. Sci. USA 96, 10326-10331 (1999).
33. Reiss, M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncol. Res. 9, 447-457 (1997).
34. Botti, C., Seregni, E., Ferrari, L., Martineti, A. & Bombardieri, E. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers 13, 51-69 (1998).
35. Korkolopoulous, P., Kaklamanis, L., Pezzella, F., Harris, A.L. & Gatter, K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Brit. J. Cancer 73, 148-153 (1996).
36. Seliger, B. et al. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol. 24, 1275-1279 (1996).
37. Dejardin, E. et al. Regulation of major histocompatibility complex class I expression by NF-kappaB-related proteins in breast cancer cells. Oncogene 16, 3299-3307 (1998).